Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials

Conference Reports for NATAP

18th European AIDS Conference
October 27th-30th, 2021
Online & United Kingdom


Efficacy and Safety Outcomes by BMI Category Over 48 Weeks in Phase 3/3b Cabotegravir and Rilpivirine Long-Acting Trials

	18th European AIDS Conference Oct 27-30- Virtual & London, UK